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Background: Cerebral ischemia has been shown to induce activation of matrix metalloproteinases (MMPs),
particularly MMP-9, which is associated with impairment of the neurovasculature, resulting in blood–brain barrier
breakdown, hemorrhage and neurodegeneration. We previously reported that the thiirane inhibitor SB-3CT, which
is selective for gelatinases (MMP-2 and −9), could antagonize neuronal apoptosis after transient focal cerebral
ischemia.
Results: Here, we used a fibrin-rich clot to occlude the middle cerebral artery (MCA) and assessed the effects of
SB-3CT on the neurovasculature. Results show that neurobehavioral deficits and infarct volumes induced by
embolic ischemia are comparable to those induced by the filament-occluded transient MCA model. Confocal
microscopy indicated embolus-blocked brain microvasculature and neuronal cell death. Post-ischemic SB-3CT
treatment attenuated infarct volume, ameliorated neurobehavioral outcomes, and antagonized the increases in
levels of proform and activated MMP-9. Embolic ischemia caused degradation of the neurovascular matrix
component laminin and tight-junction protein ZO-1, contraction of pericytes, and loss of lectin-positive brain
microvessels. Despite the presence of the embolus, SB-3CT mitigated these outcomes and reduced hemorrhagic
volumes. Interestingly, SB-3CT treatment for seven days protected against neuronal laminin degradation and
protected neurons from ischemic cell death.
Conclusion: These results demonstrate considerable promise for the thiirane class of selective gelatinase inhibitors
as potential therapeutic agents in stroke therapy.
Keywords: Embolic stroke, Focal ischemia, Gelatinase proteolysis, Intracerebral hemorrhage, Neuroprotection,
Neurovascular unit, PericytesBackground
Stroke is a devastating cerebrovascular disease with an
estimated 800,000 cases each year and mortality data from
2006 indicated that stroke accounted for approximately 1
out of every 18 deaths in the U.S. [1]. Acute ischemic
stroke is the most common form of stroke and is majorly
caused by thrombosis or embolism in the cerebral arteries.* Correspondence: guze@health.missouri.edu
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reproduction in any medium, provided the orBlockage of blood flow (ischemia) results in oxygen
deprivation, glucose deficiency in the affected region, and
infarction in the brain. Cerebral ischemia initiates cas-
cades of pathological events, including vasogenic edema,
disruption of the blood–brain barrier (BBB), intracerebral
hemorrhage (ICH), astroglial activation, and neuronal
death [2,3]. Although the molecular mechanisms under-
lying these outcomes have not yet been fully addressed,
there is considerable evidence supporting the important
role of matrix metalloproteinases (MMPs) in mediating
ischemia-induced neurovasculature impairment. Increased
expression and activation of MMPs, and gelatinases in. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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city-induced disruption of cell-matrix homeostasis and
neuronal cell death [4,5]. MMPs also play a role in
thrombolysis-mediated BBB leakage and edema, resulting
in ICH. In clinical settings, MMP-mediated neurotoxicity
and hemorrhagic transformation during the acute phase
of cerebral ischemia are frequently complicated upon
treatment with tissue plasminogen activator (tPA) [6]. In
addition, gelatinases function in neurovascular remodeling
and microvascular recanalization [2,7,8].
MMPs comprise a family of zinc-containing endopro-
teases that degrade components of the extracellular
matrix (ECM) and tight-junctions in the brain. MMPs
are also needed for modulating interactions between
cells during development and tissue remodeling [5,7].
Reportedly, unregulated MMP activity contributes to
neurological disorders, including stroke and other in-
flammatory responses. MMP-9 activity, in particular, is
significantly elevated in humans after stroke [9-11]. High
plasma MMP-9 concentrations in the acute phase of a
cerebral infarct are considered as independent predictors
of hemorrhagic transformation in all stroke subtypes
[12]. We and others have shown that aberrant MMP-9
proteolytic activity is associated with an increase in BBB
permeability, which results in brain edema and
hemorrhage, and contributes directly to neuronal injury,
apoptosis and brain damage after acute cerebral ische-
mia [13-16]. Moreover, cerebral infarct size is reduced in
mice deficient in MMP-9, or after treatment with MMP
inhibitors [17].
Among the different cell types in the neurovasculature,
pericytes are known to play a role in safeguarding the brain
against injury, and control key neurovascular functions and
neuronal phenotype in the adult and aging brain [18-20].
Loss of pericytes, associated with accumulation of neuro-
toxic and vasculotoxic macromolecules in the brain, could
reduce brain microcirculation, diminish brain capillary per-
fusion, and disrupt the BBB, leading to vascular damage.
Analysis of pericyte-deficient mice (e.g., with Pdgfb
mutants) reveals that pericyte deficiency leads to increased
permeability of the BBB, which probably occurs by facilitat-
ing endothelial transcytosis [18]. Although MMP-9 inhib-
ition or knockout can attenuate proteolysis of BBB [13,17],
more recent studies suggest its possible role in neurovascu-
lar regeneration, especially in the delayed phase of cerebral
ischemia [21]. Thus, successful anti-stroke therapies require
selective inhibition of aberrant activity without altering the
physiological function of MMPs, such as their roles in
axonal growth, synaptic plasticity, and vascularization in
the central nervous system [22-26].
Pathologically activated therapy (PAT) is a novel neuro-
protective strategy based on the principle that drugs are
activated during the pathological state of the target, while
sparing normal tissue function [27]. One PAT strategy isthe target-induced activation of MMP inhibitors. Specific-
ally, (4-phenoxyphenylsulfonyl)methylthiirane (referred to
as SB-3CT) is the first mechanism-based MMP inhibitor
selective for gelatinases [28]. Active gelatinases bind to
SB-3CT and catalyze the opening of the thiirane ring in the
molecule. The resultant species generated within the active
site of the enzyme affords tight binding between the inhibi-
tor and the enzyme. That is to say, the activity of the
enzyme generates the potent inhibitory species within the
active site. This mechanism-based inhibition confers a PAT
strategy to abrogate the deleterious activity of gelatinases,
making this class of inhibitors potentially suitable for more
prolonged treatment, because of the selectivity that it
affords. We first reported that SB-3CT prevents proteolysis
of the ECM basement membrane laminin and rescues neu-
rons from focal cerebral ischemia [29]. Most importantly,
significant therapeutic benefit can be observed for up to 6
hours after initial injury. Recent studies show that SB-3CT
abolishes oxygen-glucose deprivation-induced reduction of
the tight junction protein occludin as well as decreases
Evans blue extravasation and apoptotic cell death after
spinal cord injury, subarachnoid hemorrhage [30-32], and
cardiopulmonary resuscitation-induced BBB disruption
[33]. These results are consistent with the notion that inhi-
biting pathological gelatinolytic activity can maintain the
brain neurovascular integrity and protect it from ischemia
or other neurovascular insults.
In the present study, we use a fibrin-rich blood clot to in-
duce middle cerebral artery (MCA) occlusion in mice. This
embolus-induced focal cerebral ischemia model is more
physiologically relevant to thromboembolic stroke in
humans. We demonstrate the protective effects of SB-3CT
on the neurovascular unit, and document that SB-3CT can
manifest inhibitory activity even in the presence of an em-
bolus blocking the MCA and its branches. We disclose that
repeated-dose administration of SB-3CT over seven days
in the embolus-induced “permanent” focal cerebral ische-
mia model also protects the brain from neurovascular
impairment with no apparent cytotoxicity.
Results
Embolus-induced focal cerebral ischemia in mice
To evaluate the effects of the selective gelatinase inhibitor
SB-3CT, we employed a modified version of a previously
described embolic focal ischemic model [34]. This model
was created by delivery of a 10-mm long, fibrin-rich autolo-
gous clot into the stem of the right MCA. To ensure MCA
occlusion and to determine distribution of the embolus
lodgments, we harvested the brains with intact vasculature
24 hours after clot injection and examined the patterns of
the embolus blocking the right MCA (Figure 1A). Injection
of a clot labeled with fluorescent dye marked the location
of the embolus within the circle of Willis at the origin
of the right MCA (Figure 1B). In most cases (31 out of
Figure 1 Patterns of embolus blocking the MCA. a A representative picture showing the site of the embolus blocking the right MCA at the
circle of Willis. After injection of clot, mice were transcardially perfused with saline and the brain was removed. b The position of embolus was
confirmed by injection of clot labeled with fluorescent dye, marking blockage of the right MCA. c Identification of embolus positions (P) in brain
24 hours after ischemia. P1 (P1a–P1c together) indicates complete blockage of the MCA, P2 indicates that an embolus did not reach the MCA, P3
indicates that an embolus was lodged in the second branch of the MCA, P4 indicates that an embolus was lodged in the third branch of the
MCA, and P5 indicates that no embolus was seen. Number of animals (n) in each position is shown in parenthesis. d Validation of embolus-
induced MCA blockage by FITC-dextran infusion. A representative coronal section from a brain after venous infusion of FITC-dextran showing
infarct area in the right MCA supplied regions (marked by dashed white lines) 24 hours after embolus-induced ischemia. Perfusion of FITC-dextran
marks the microvessels in the unlesioned brain regions. In the peripheral part of the infarct cortex, high intensity of FITC-dextran indicates
leakage of the 2,000 kDa macromolecule from microvessels into the infarct area. Section thickness, 100 μm; Scale bar, 800 μm.
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intracranial segment of the internal carotid artery at the
origin of the MCA, designated as position P1 (Figure 1C).
In a few cases (3 of 44; <7%), the embolus occluded the
MCA at further branches at positions P3 to P4. The occlu-
sion at position P2 (8 out of 44, 18.2%) indicated that the
embolus did not reach the origin of the MCA. In rare cases
(2 of 44; 4.5%), clots were not found (P5 in Figure 1C). This
is likely due to inherent variations in the procedure of
embolus preparation. We have eliminated variations bystandardizing the washing steps and selecting homogenous,
smooth and well-formed clots for MCA injection.
Next, we examined the embolic blockage of the MCA-
supplied microvasculature by intravenous infusion of a
fluorescence-labeled macromolecule. Confocal microscopy
with fluorescein isothiocyanate (FITC)-dextran (2,000 kDa)
revealed the embolus-blocked microvasculature as marked
by dashed white lines in a representative serial brain sec-
tion, indicating the presence of infarct (Figure 1D). As
expected, the contralateral side (left intracranial segment)
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of the embolic region by cresyl violet staining revealed ex-
tensive cell death with small-condensed nuclei in the ische-
mic hemisphere (data not shown).
Moreover, we compared the mouse embolus-induced
MCA occlusion to the filament model in which a filament
was inserted for two hours followed by reperfusion.
Reports from our laboratory and others have indicated
that transient MCA occlusion longer than two hours leads
to considerably large infarct volumes in the cortex, as well
as neuronal death in the hippocampus and striatum of the
affected hemisphere [2-4]. This model also shows impair-
ment of neurovasculature, as well as an identifiable pen-
umbra of astrogliosis (data not shown). In both the
embolic and filament models, there were similar declines
in regional cerebral blood flow (rCBF) levels to 25% of
baseline and no significant difference in rCBF was
observed during the two-hour ischemia phase (Figure 2A).
Similarly, comparable neurobehavioral scores and infarctFigure 2 Comparison of the embolic versus filament ischemia models
There was no significant difference in rCBF in two-hour ischemia between
relative to pre-ischemic baselines in 79% (68 out of 86) of the animals with
Behavioral tests of motor, sensory and reflex function scored using the mN
indicated no statistically significant difference between embolic and filame
behavioral scores. c Infarct volume quantified by 2,3,5-triphenyl-tetrazolium
in infarct volumes in the two models; p> 0.05, by one-tailed Student’s t-te
data are expressed as means ± SEM. These results indicate that both focalvolumes were observed 24 hours after both embolic and
filament-induced MCA occlusion (Figures 2B and 2C).
SB-3CT reduces infarct volume and ameliorates
behavioral functions after embolic cerebral ischemia
We previously reported that SB-3CT could rescue neu-
rons from transient focal cerebral ischemia [29]. Here, we
evaluated the efficacy of SB-3CT in the embolic model
after intraperitoneal (ip) administration at 25 mg/kg at 2
and 4 hours post-ischemia, and examined neurobehavioral
outcomes and potential protective effects against brain
damage. As previously observed, SB-3CT treatment did
not alter physiological indices, including arterial blood gas
and glucose levels, as compared to vehicle-treated animals
[29]. The mean infarct volume in vehicle-treated mice, as
indicated by staining of brain sections with 2,3,5-triphe-
nyl-tetrazolium chloride (TTC, Figure 3A), was 33% of
the total hemisphere after accounting for edema
(Figure 3B) [17,34,37]. Post-ischemic treatment with. a rCBF index before and during ischemia, as well as after reperfusion.
mice with either type of ischemia. rCBF showed a 75% reduction
embolic ischemia, comparable to the previous reports [29,34-36]. b
SS on a scale from 0 to 14 (0 = normal, 14 =maximal deficit). Analysis
nt models; p> 0.05, one-tailed Student’s t-test for the sum of
chloride (TTC) staining. No statistically significant difference was seen
st. Number of animals (n) in each group is shown in parenthesis, and
cerebral ischemia models are comparable.
Figure 3 SB-3CT protects against brain damage and ameliorates neurobehavioral deficits after embolic MCA occlusion in mice. Mice
were injected ip with SB-3CT (25 mg/kg body weight) or vehicle 2 and 4 hours after embolus-induced focal cerebral ischemia. Neurobehavioral
tests were conducted 24 hours later and scored using the 14-point mNSS, followed by assessment of infarct volume by TTC staining. a
Representative images of TTC staining. b Quantification of infarct volumes analyzed by TTC staining using ImageJ tools. *, p< 0.05 by one-tailed
Student’s t-test. c Improvement in motor and sensory function following post-ischemic SB-3CT treatment compared to the vehicle-treated
controls; *, p< 0.05 for motor; ***, p< 0.001 for sensory; and **, p< 0.01 for the sum of the behavioral scores, respectively, by one-tailed
Student’s t-test. Number of animals (n) in each group is shown in parenthesis, and data are expressed as means ± SEM, whereas reflex activity was
unchanged.
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reduced infarct volume to about 20% of the total hemi-
sphere (Figure 3B). Neurobehavioral outcomes based
on motor, sensory functions, and reflex activity were
assessed at 24hours using the 14-point modified
neurological severity scoring (mNSS) measurement
protocol (see Methods) [37]. SB-3CT treatment ame-
liorated neurobehavioral outcomes, particularly in the
motor and sensory functions (Figure 3C). These find-
ings indicate that SB-3CT confers protection to brain
cells, despite the presence of the embolus.
SB-3CT inhibits MMP-9 activity in the embolus-induced
ischemic brain
To determine whether SB-3CT administration inhibits
gelatinolytic activity after embolus-induced focal ischemia,
we examined the brain tissues by gelatin zymography. The
analysis revealed increases in proMMP-9 and active MMP-
9 levels in the ischemic hemisphere after embolus-induced
MCA occlusion. SB-3CT treatment attenuated both
proMMP-9 expression and the level of active MMP-9(Figure 4). Although the mechanism for attenuation of
proMMP-9 expression by SB-3CT is not well under-
stood, there is evidence of a feedback loop for modula-
tion of the proMMP-9 expression by transcription
factors such as NF-kappa B and AP-1 [5]. Under these
conditions, we did not observe any variation in the
levels of the proform of MMP-2 (proMMP-2; Figure 4A).
This is consistent with previous findings of the presence
of constitutively expressed proMMP-2 and inductively
expressed MMP-9 in transient ischemia or spinal cord
injury models in rodents [29,30], and in humans after
the onset of stroke [9-11].
SB-3CT protects laminin-positive pericytes from
embolus-induced ischemic lesion by relieving them from
gelatinase-mediated lumen contraction after embolic
MCA occlusion
We have previously shown that degradation of laminin
after focal cerebral ischemia involves MMP-9 activation
[29]. Other studies have also shown that pericytes play a
role in constriction of the vascular wall, leading to
Figure 4 SB-3CT inhibits elevated MMP-9 activity after embolus-induced MCA occlusion in mice. a Gelatin zymography reveals increased
levels of MMP-9 zymogen (proMMP-9) and activated (act.MMP-9) enzyme in embolus-induced focal cerebral ischemia, and SB-3CT treatment
attenuated the increase in proMMP-9 and act.MMP-9. Under these experimental conditions, proMMP-2 was not altered. b Quantification of
relative MMP-9 gelatinolytic activity (n = 3) *, p< 0.05 by one-tailed Student’s t-test; data are expressed as means ± SEM.
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ischemia in the adult brain [19,20]. To investigate the
effects of SB-3CT on gelatinase-mediated proteolysis of
laminin after embolic ischemia in mice, we used triple-
color confocal imaging of the well-established pericyte
markers α-smooth muscle actin (α-SMA), chondroitin
sulfate proteoglycan NG2, and desmin. We also immu-
nostained laminin, an ECM component, to visualize
brain capillary vascular profiles and then examined brain
sections from ischemic mice for the effects of pericytes
on lumen diameter. Deconvolution microscopy revealed
that α-SMA immunoreactivity colocalized with the peri-
cyte markers NG2 and desmin, and the merged images
showed an encircled lumen structure (Figure 5A). The
specificity of the pericyte markers was confirmed by
immunohistochemistry for monoclonal antibodies NG2,
desmin, or α-SMA (Additional file 1: Figure S1).
By double immunostaining for laminin and α-SMA, we
compared mice treated with SB-3CT to vehicle-treated
animals in both the ischemic cortex and the contralateral
region. This experiment examined the effects of SB-3CT
on gelatinase-associated laminin degradation and changes
in the lumen diameter by pericytes. Pericytes were seen as
annular cells surrounding the vascular lumen in the non-
ischemic cortex (Figure 5A), with average lumen diameters
of 5~ 10 μm. We further observed significant decreases in
laminin-positive pericytes (Figures 5B and 5C) and peri-
cyte-encircled lumen diameters in the ischemic penumbral
cortex compared to the contralateral regions (Figure 5D).
A higher magnification of the α-SMA-positive pericytes
showed pericyte lumen contraction after embolus-induced
cerebral ischemia (Additional file 2: Figure S2), suggesting
that embolic ischemia caused loss of α-SMA-positive peri-
cytes and increased pericyte lumen contraction. In the
ischemic penumbral cortex, SB-3CT treatment protected
laminin-positive pericytes by significantly increasing their
numbers and the average pericyte lumen diameter
(Figures 5C-5D). These results indicate that SB-3CT canreduce the loss of laminin-positive pericytes, relieve them
from ischemic contraction and restore microvascular
patency, thus protecting against neurovascular impairment
in embolus-induced focal ischemia in mice.
SB-3CT attenuates gelatinase-mediated impairment of the
neurovascular unit and reduces intracerebral hemorrhage
in ischemic mice
We and others have shown that activated MMP-9 directly
induces neuronal apoptosis and hemorrhage, and that
SB-3CT treatment can protect against neurotoxicity, BBB
disruption and hemorrhage [29,31,38]. In this study, we
evaluated whether SB-3CT had any effect on reducing
secondary hemorrhages after embolic ischemia in mice by
examining embolic stroke-induced hemorrhages using
brain sections stained with cresyl violet, as described previ-
ously [39]. Cresyl violet-stained brain sections revealed
scattered secondary micro-hemorrhages in the ische-
mic cortex (Figure 6A). We further quantified micro-
hemorrhagic volumes with the stereology technique
[39]. Results show that while the average micro-
hemorrhage in the ischemic brains was more than
300 μm3, SB-3CT treatment significantly decreased
ICH volumes to less than 100 μm3 (Figure 6B).
Next, we investigated the effects of SB-3CT on the in-
tegrity of neurovasculature by examining microvascular
endothelial cells using the specific endothelial marker
glycoprotein Lycopersicon esculentum (tomato) lectin-
FITC and the BBB tight-junction protein ZO-1. Fluores-
cence staining revealed that microvascular lectin-FITC
immunoreactivity colocalized with the well-documented
antibody marker CD31 for endothelial cells (Additional
file 3: Figure S3). We observed loss of microvascular endo-
thelial cells in the embolus-induced ischemic cortex
(Figure 6C). In contrast, SB-3CT protected against endo-
thelial deformation and antagonized the loss of lectin-
positive brain capillary endothelial cells. We also observed
gelatinase-mediated degradation of the tight-junction
Figure 5 SB-3CT protects pericytes from ischemia-induced contraction and cell loss after embolic MCA occlusion in mice. a
Colocalization of α-SMA-positive immunoreactivity with pericyte markers NG2 or desmin in the unlesioned cortex. NG2 or desmin monoclonal
antibody (mAb) was used to detect pericytes with anti-mouse IgG-Alexa488 (green), followed by immunostaining with α-SMA mAb which was
visualized by anti-mouse IgG-Alexa594 (red). Scale bar, 8 μm. b Representative images of ischemic cortex penumbras as compared to the
corresponding contralateral regions in mice treated with SB-3CT or vehicle-treated control. Vascular cells showing colocalized (yellow) staining are
laminin-positive pericytes. Top row: Pericytes identified by α-SMA appear as annular cells surrounding the lumen in the non-ischemic cortex.
Middle row: Constricted vascular lumens were surrounded by contracted α-SMA immunostaining. The number of laminin-positive pericytes in the
ischemic region was significantly decreased compared to the non-ischemic cortex. Bottom row: Contraction of pericytes and loss of laminin-
positive pericytes were protected by SB-3CT treatment. Scale bars: 50 μm. c Quantification of the percentage of laminin-positive pericytes in
cortex after treatment with SB-3CT or vehicle. Data were analyzed by one-tailed Student’s t-test: *, p< 0.05 compared ischemic hemisphere to
contralateral hemisphere (paired t-test); #, p< 0.05 compared the difference between contralateral and ischemic hemisphere after SB-3CT
treatment to that of the vehicle-treated control (unpaired t-test). d Quantification of the mean diameters of pericyte-encircled lumens. The
average lumen diameter was calculated in approximately 300 pericytes from 4–5 randomized cortical areas of the ischemia penumbral region
and the corresponding contralateral hemisphere in each brain (n = 3 in each group). Pericyte-encircled lumen diameters in the ischemic cortex
were compared to those in the contralateral side treated with SB-3CT or vehicle. *, p< 0.001 compared to the non-ischemic cortex; #, p< 0.05
compared the difference between contralateral and ischemic hemisphere after SB-3CT treatment to that of the vehicle-treated control; data in
panels C and D are expressed as means ± SEM.
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the ischemic cortex (Additional file 4: Figure S4). These
findings were similar to those previously reported by us
and others [13,15,17,29,38]. Taken together, these data
indicate that an impaired neurovasculature leads to sec-
ondary micro-hemorrhages and that SB-3CT protects
against gelatinase-mediated neurovasculature impairment
in embolic ischemia.
Repeated-dose SB-3CT treatment attenuates degradation
of neuronal laminin, protects neurons from ischemia and
improves neurobehavioral outcomes after embolic MCA
occlusion
Because of the unique mechanism of action of SB-3CT and
its selectivity for gelatinases, repeated-dose SB-3CT treat-
ment for seven days significantly antagonized neurovascularimpairment by attenuating gelatinase-mediated neuronal
laminin degradation (Figure 7A), and protecting neurons
from cell death, as observed by cresyl violet staining
(Figure 7B) and Fluoro-Jade B for neurodegeneration
(Additional file 5: Figure S5). SB-3CT also ameliorated
the mNSS 14-point neurobehavioral outcomes, par-
ticularly the sensory functions in the embolus-induced
ischemia brains (Figure 7C).
Discussion
In the present study, we investigated the selective gelatinase
inhibitor SB-3CT in a mouse model of embolus-induced
“permanent” focal cerebral ischemia. We demonstrated the
following key findings: (1) the autologous blood clot em-
bolus model is a reliable, physiologically induced focal
ischemia model, highly relevant to thromboembolic stroke
Figure 6 SB-3CT attenuates gelatinase-associated loss of endothethial cells and decreases ICH. a Representative brain sections stained
with cresyl violet reveal secondary micro-hemorrhages in the ischemic cortex after embolic stroke in mice. Top panels: A lower magnification of
serial sections, which are separated in 960 μm intervals for adjacent sections. Lower panels: Higher magnification of the cresyl violet-stained brain
sections (separated in 200 μm intervals for two adjacent sections), in the ischemic cortex 1 day after treatment with either vehicle (a-d) or SB-3CT
(a’-d’). Scale bar, 300 μm. b Quantification of hemorrhagic volume. Micro-hemorrhages were evaluated in cresyl violet-stained brain sections by
bright-field microscopy. ICH volumes were quantified using the stereology technique, which utilizes systematic sampling of 25–30 serial sections
per brain, each section separated by 200-mm along the anteroposterior axis of the mouse brain. Analysis of the ICH volumes revealed that SB-
3CT significantly reduced ICH volume in ischemic brains (n = 3), p< 0.05 by one-tailed Student’s t-test, and data are expressed as means ± SEM. c
Fluorescence staining shows loss of lectin-positive endothelial cells in the embolic ischemic cortex. SB-3CT blocks deformation of endothelial cells
in the ischemic cortex. Scale bar, 50 μm.
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can inhibit MMP-9 activity in vivo, attenuate ECM base-
ment membrane laminin degradation, prevent pericyte
lumen from contraction, and protect pericytes and endo-
thelial cells, thus playing an important role in preserving
neurovascular integrity and reducing hemorrhage; and (3)
repeated-dose SB-3CT treatment can counteract degrad-
ation of neuronal laminin, protect neurons from ischemic
cell death, and ameliorate neurobehavioral outcomes after
embolic MCA occlusion in mice.
The rodent embolus model has distinct advantages in
testing anti-thrombolytic and neuroprotectant agents forcerebral ischemia and is recommended by the Stroke
Therapy Academic Industry Roundtable (STAIR) [40]. In
our embolic model, the MCA supporting the brain region
blocked by the embolus shows insufficient perfusion com-
pared to the contralateral hemisphere. This model mimics
the pathological conditions of an autologous clot-induced
MCA occlusion. Initially, one of our goals was to test the
reliability of the embolus model in comparison with the
widely used filament model [29,34-36]. We also aimed to
extend previous studies with the selective gelatinase in-
hibitor SB-3CT in the embolus model in mice, and further
evaluate the suitability of the selective gelatinase inhibitor
Figure 7 SB-3CT treatment for 7 days attenuates degradation of neuronal laminin, protects neurons from ischemic cell death, and
ameliorates neurobehavioral outcomes after embolic MCA occlusion. Mice were ip injected with SB-3CT or vehicle 2 and 4 hours after MCA
occlusion, and then once a day from post-ischemia days 1 to 6. a Immunohistochemistry of representative cortical regions for the ECM
component laminin (green) and neuronal markers, MAP-2 and NeuN (red), with DNA counterstain Hoechst 33324 (blue). Scale bar, 75 μm.
Representative images revealed that there was loss of laminin-positive neurons after embolus-induced cerebral ischemia, while SB-3CT
significantly attenuated neuronal laminin degradation and protected neurons from ischemic cell death. b Quantification of neuronal damage
based on cresyl violet staining. Cellular damage in each region was scored as 0, normal (no apparent neuronal cell death); 1, fewer than 1/3 cells
damaged; 2, more than 1/3 but less than 2/3 damaged; and 3, more than 2/3 of cells dead. Damage was determined 7 days after MCA occlusion.
c Repeated-dose administration of SB-3CT improves sensory functions. *, p< 0.05 by one-tailed Student’s t-test for comparisons of the vehicle- vs.
SB-3CT-treated groups. Number of animals (n) in each group is indicated in parenthesis, and data are expressed as means ± SEM.
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for 7 days. Results from this study indicate that the em-
bolus model can be used to test thrombolytic or neuro-
protective agents.
In the developing and adult brains, MMP proteolytic ac-
tivity is known to play roles in modulating diverse physio-
logical functions in the central nervous system, such as
ECM remodeling, myelin turnover, axon outgrowth, angio-
genesis, long-term potentiation, and synaptic plasticity in
memory and spatial learning [5,7,25,26]. However, these
enzymes also play important roles in mediating patho-
logical processes, especially after stroke or traumatic injur-
ies [5,7]. Elevated MMP-9 activity is correlated with BBBdisruption, brain edema, hemorrhagic transformation, and
neuronal apoptosis [2,4,12,13]. There is evidence indicating
that specific inhibition of MMP activity during stroke onset
or immediately following brain injury likely improves
neurological outcomes. Lo and colleagues reported that
minocycline, a broad-spectrum MMP inhibitor, could re-
duce neuronal cell death after ischemia and extend the
thrombolytic time window [41]. Moreover, MMP-9 knock-
out can stabilize the BBB by preventing degradation of the
tight-junction protein ZO-1 [17]. During ischemic stroke,
MMP-9 inhibition also mitigates BBB disruption and
reperfusion injury experimentally induced by the thrombo-
lytic agent tPA, a therapeutic agent that can itself increase
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that minocycline can lower plasma MMP-9 levels, even at
72 hours after stroke, and improve neurological outcomes
in acute ischemic stroke patients treated with tPA [11]. In
the present study, using the embolus-induced ischemia
model, treatment with SB-3CT revealed an unexpected
finding as compared to the control group. During ische-
mia, expression of inactive proMMP-9 increased signifi-
cantly, a small portion of which was processed to active
MMP-9, which manifests the pathological consequences of
ischemia. When ischemic animals were treated with SB-
3CT, we observed a general down regulation of proMMP-9
expression. This could be the consequence of a feedback
process whereby active MMP-9 interacting with SB-3CT
via its thiolate acts on an unknown downstream target to
modulate the MMP-9 expression by transcription factors
such as NF-kappa B and AP-1 [5].
MMPs have been implicated in beneficial roles in re-
covery following stroke. Shortly after ischemic insult, a
cascade of events is initiated in attempt to repair the
damage, a process similar to that found in wound healing
[5,7]. Following injury, blood vessels are dependent on the
plasminogen-activator system and on MMPs for their re-
generation [42]. For example, Lo and colleagues showed
that delayed inhibition of MMPs by broad-spectrum inhi-
bitors is detrimental during the ischemic recovery stage
seven days after cerebral ischemia, hindering brain repair
in mice, and attenuating neurovascular regeneration in
the penumbra [21]. Perhaps, a suitable balanced level of
MMP-9 activity is important for vascular remodeling after
spinal cord injury [22]. Therefore, extended inhibition of
MMPs, especially through the use of broad-spectrum
inhibitors, might prove deleterious [2,5].
In the present study, we observed that the mNSS
scores of both motor and sensory functions after
two-doses of SB-3CT on day 1 are significantly lower,
compared to the vehicle-treated group (Figure 3C).
Moreover, repeated-dose administration of SB-3CT for
seven days appears to offer beneficial effects after em-
bolic ischemic injury, as demonstrated by its ability to
attenuate degradation of neuronal laminin, protect neu-
rons from ischemia shown on cresyl violet stained brain
sections and ameliorate neurobehavioral outcomes
(Figure 7). These data are in line with the decrease in
infarct volume and the ability of SB-3CT to protect the
brain from ischemic damage. Measurement of the sen-
sory functions showed significant improvement at the
end of the seven-day SB-3CT treatment, but no further
change in motor function (Fig. 7C). However, we
observed that mice in the vehicle-treated group had sig-
nificantly improved motor functions by seven days after
ischemia, as indicated by a diminution in their motor
function mNSS from a score of 5 at day 1 to a score of 2
at day 7. It has been shown that rodents are able torecover gradually in motor function after ischemic
insult despite persistence of the infarct area [43,44]. These
observations for the improvement in motor function might
be due to compensatory effects of the endogenous neuro-
genic response and/or subsequent retrieval of interhemi-
spheric functional connectivity within the sensorimotor
system in rodents. Nevertheless, repeated-dose administra-
tion of SB-3CT for seven days offered beneficial effects,
such as protecting neurons and ameliorating neurobeha-
vioral functions in stroke outcomes relative to vehicle-
treated mice. On the other hand, delayed treatment with
the broad-spectrum MMP inhibitors FN-439 (day 3 or 7)
and BB-94 (day 7) significantly worsened infarct volumes
[21]. Since these broad-spectrum MMP inhibitors are pep-
tidomimetics and they were administered intraventricularly
[21], they are unlikely to cross the BBB. In contrast, SB-
3CT crosses the BBB in healthy animals (unpublished
data). These data suggest the benefit of selective gelatinase
inhibitors over broad-spectrum MMP inhibitors [27].
Using the embolic model for “permanent” MCA oc-
clusion in mice, we documented the protective effects
of SB-3CT on the neurovascular unit. Since SB-3CT is a
small molecule that distributes to the brain, it enters the
brain via the unaffected vasculature, and diffuses to the
infarct regions to manifest its inhibitory activity. In this
study, we demonstrated the protective effects of SB-
3CT despite the fact that the embolus remained intact
in the brain during the course of treatment. As such,
this inhibitor is considered a PAT agent. The basis of
the selectivity of SB-3CT is the ability of gelatinases to
catalyze a requisite thiirane-ring opening of the SB-3CT
structure [45]. The thiolate, formed only within the
active site of gelatinase, is capable of coordinating with
the active-site zinc ion, and precipitates potent “slow-
binding” inhibition, a hallmark of this class of inhibitors.
Inhibition inherent to this class of compounds sup-
presses pathological activity of the target gelatinase,
which is activated during the diseased state [27]. Under
this condition, the inhibitory effect of SB-3CT is limited
to gelatinases. In addition to stroke, this mechanism-
based, selective gelatinase inhibitor can exhibit promis-
ing efficacy on other diseases. For example, recent
studies demonstrated that SB-3CT attenuates BBB dam-
age by decreasing oxygen-glucose deprivation-induced
occludin degradation in early ischemic stroke, protects
against oxidative stress-mediated apoptosis after spinal
cord injury, and increases proliferation of NG2 progenitor
cells after spinal cord injury [30,32,46]. Another study
showed that SB-3CT could prevent laminin degradation
and ameliorate neuronal death in a rat model of subarach-
noid hemorrhage [31]. Taken together, these studies along
with the recent findings of SB-3CT on neurovasculature
[8,20], indicate that SB-3CT has promise in the treatment
of gelatinase-mediated diseases. The inhibitor also exhibits
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tegrity and protective effects on neuroinflammation against
degradation of ECM components, pericyte lumen contrac-
tion, BBB disruption, neuronal apoptosis, and hemorrhagic
transformation in brain and spinal cord injuries.
Brain function and neuronal viability are dictated by
the adequate delivery of oxygen and glucose through
cerebral microvessels. Because of their small diameter
and relatively low flow velocity, microvessels are prone
to occlusion by thromboembolism. Substantial evidence
indicates that pathological MMP-9 activity after cerebral
ischemia degrades components of the ECM and tight-
junctions, thus contributing to microvessel and BBB
leakage [13,17]. We previously showed that MMP-9 ac-
tivation is essential for degradation of laminin after focal
cerebral ischemia [29]. Pericytes are known to play a
role in modulating capillary diameter by constricting
the vascular wall, a process that can obstruct capillary
blood flow during ischemia in the adult brain [20]. In
this study, we observed a significant decrease in
laminin-positive pericytes, and an increase in pericyte
lumen contraction in the ischemic cortex (Figure 5). Be-
cause oxidative and nitrosative stress might promote
capillary constriction after ischemia, and S-nitrosylation
contributes to MMP-9 activation after stroke [16], it is
reasonable to consider pericytes as critical targets for
MMP-9 proteolytic activity after cerebral ischemia. The
ability of SB-3CT to protect laminin-positive pericytes,
and inhibit lumen contraction after embolic MCA oc-
clusion is critical for its efficacy in restoring micro-
vascular patency and protecting against neurovascular
impairment. Moreover, the ability of SB-3CT to attenuate
gelatinase-mediated damage of endothelial cells and BBB
tight-junction ZO-1 and to protect against endothelial
deformation is important in its ability to decrease ICH in
ischemic mice.
Conclusions
In summary, we used an embolic cerebral ischemia
mouse model to evaluate SB-3CT, a mechanism-based
selective and potent gelatinase inhibitor. We demon-
strated MMP-9 activation and neurovasculature impair-
ment in stroke, and showed the ability of SB-3CT to
inhibit MMP-9 activity in vivo, which resulted in main-
tenance of laminin, antagonism of pericyte contraction
and loss, and preservation of laminin-positive pericytes
and endothelial cells. Thus, SB-3CT rescued neurons
from apoptosis and prevented ICH. Selective targeting of
MMP-9 antagonizes disruption of the neurovascular unit
and protects against brain damage and vessel constric-
tion. Taken together, these results strongly indicate that
thiirane class of gelatinase selective inhibitors holds
great promise as therapeutic agents for the treatment of
stroke.Methods
Animal models of focal cerebral ischemia in mice
Adult male C57Bl/6 J mice (The Jackson Laboratory, Bar
Harbor, Maine, USA), 6–9 weeks of age and weighing
20–28 g were housed in a 12 hours light/dark cycle and
permitted food and water intake ad libitum . All groups
in the animal experiments were performed in a rando-
mized, blinded manner at the University of Missouri
according to an institutionally approved protocol in ac-
cordance with the National Institutes of Health Guide
for the Care and Use of Laboratory Animals. Mice were
anesthetized with isoflurane (1–1.5%) masked with a gas
mixture of 30% oxygen and 70% nitrogen. Rectal tem-
peratures were maintained at 37 ± 0.5°C with animals
placed on a thermostat-controlled heating pad.
Two mouse models of focal cerebral ischemia were
used: an embolic model using autologous clots to oc-
clude the MCA and a filament model described previ-
ously [29,34-36]. For the latter, C57BL/6 J mice were
subjected to right MCA occlusion by insertion of a 6–0
monofilament to block the MCA for 2 hours, and fol-
lowed by filament withdrawal for arterial reperfusion.
For the embolic model, homologous blood clots were
prepared by a modification of earlier methods [34].
Briefly, femoral arterial blood from a donor mouse was
withdrawn into a 3-foot long PE-50 polyethylene tubing,
incubated at 37°C for 2 hours, and cooled at 4°C over-
night to allow the formation of fibrin-rich blood clots.
Blood clots were then washed with sterile phosphate
buffered saline (PBS) in a 2-foot long PE-10 tubing for
6 ~ 8 rounds. After ejection from the PE-10 tubing, clots
were cut into 10-mm long (0.02 μl) pieces. A single
piece autologous clot was inserted via a PE-10 catheter
with a modified tip of ~0.20 mm outer diameter from
the external cerebral artery into the internal cerebral ar-
tery lumen to occlude the MCA. The catheter was im-
mediately removed after injection. Both models required
approximately 15–20 min (no longer than 20 min) from
the start of anesthesia to completion of the surgery; ani-
mals were not included in the subsequent study if the
surgery took over 20 min. A total of 94 mice were used
in the subsequent study.
SB-3CT administration
SB-3CT, a discovery from the Mobashery laboratory,
was synthesized for this study by reported methodology
[47]. Mice were divided into four groups: vehicle-treated
group and SB-3CT-treated one with treatment for either
one day or seven days after embolic MCA occlusion. SB-
3CT (12.5 mg/mL) was freshly dissolved in 25% DMSO/
65% PEG-200/10% water and filtered through an Acro-
disc syringe filter with a 0.2 μm, 13-mm diameter sterile
hydrophobic PTFE membrane (VWR, West Chester,
PA). Mice were ip injected with 2 μL/gram body weight
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embolic ischemia, followed by an additional dose at
4 hours. In repeated-dose treatment conditions, the
same dose of SB-3CT was ip administered 2 and 4 hours
after embolic ischemia, followed by once daily from
post-ischemia day 1 to 6. Earlier work indicated that ip
administration of SB-3CT does not alter mean arterial
blood pressure, pH, PCO2, and PO2 [29].
Monitoring of regional cerebral blood flow by laser
doppler flowmetry
A laser Doppler probe (Moor Instruments, Devon, UK)
was used to continuously monitor rCBF to ensure MCA
occlusion. rCBF was expressed as a percentage of pre-is-
chemic baseline values. A total of 86 mice were used for
embolic ischemia and approximately 80% of the mice
showing sustained MCA blockage of less than 25% of
pre-ischemic rCBF baselines were included in the subse-
quent study.
Neurobehavioral assessment
Analysis of neurobehavioral deficits was conducted by
individuals blinded to coded treatment groups. Animals
underwent neurological evaluation using the 14-point
mNSS on days 1 and 7 after embolic MCA occlusion.
Neurobehavioral outcomes of the mNSS include a com-
posite of motor, sensory and reflex tests, as described
[37]. In scoring injury, one score point was awarded for
the inability to perform a test or for the lack of a tested
reflex; thus, the higher the score, the more severe the in-
jury. Neurological function was graded on a scale of
0–14 (0 = normal, 14 =maximal deficit).
Measurement of infarct volume
After neurological assessment, mice were sacrificed with an
overdose of isoflurane and transcardially perfused with PBS
to remove intravascular blood and brains were rapidly har-
vested. Coronal brain sections (1 mm thick) were stained
with 2,3,5-triphenyltetrazolium chloride (TTC, Sigma, St.
Louis, MO). Infarct volumes were quantified using the Ima-
geJ analysis software, where TTC lesion areas from each
slice were integrated to yield total ischemic lesion volumes.
To minimize errors associated with edema during tissue
processing for histological analysis, infarct volume is pre-
sented as a percentage of infarct volume relative to the
volume measured in the contralateral hemisphere (indirect
volume calculation) [21,29,35].
Zymographic assays of gelatinolytic activity
Gelatin zymography was carried out as described [16].
Briefly, gelatinases were extracted in Tris-buffered saline,
pH 7.6, followed by affinity precipitation with gelatin-
Sepharose 4B. Bound material was released from the
beads using 10% DMSO; the samples were analyzed byelectrophoresis in a 10% gelatin zymogram gel under
non-reductive conditions, followed by incubation over-
night at 37°C in Tris buffer, pH 8, with 5 mM CaCl2. As
a control, EDTA was added to other samples to inhibit
all MMP activities. Gels were stained with Coomassie
blue and digitized for densitometry analysis.
Histological staining and assessment of brain damage
At days 1 or 7 after embolic ischemia, mice were sacrificed
and brains were processed for histochemical staining using
the stereology technique as described [36,39]. Briefly,
brains were dissected and submerged in 4% paraformalde-
hyde overnight at 4°C. Coronal sections were serially cut
through the entire brain at 40 μm intervals with a vibro-
tome (VT1200S, Leica Microsystems, Inc., Bannockbum,
IL), and a total of 120–150 tissue sections were sequentially
collected into a 24-well plate (e.g., a distance of 960μm in
two adjacent sections in each well). every 5th section was
reserved for histochemical staining with cresyl violet to
analyze neuronal cell death and score brain damage.
Stained sections were examined using an Olympus BX-41
upright pathology microscope (Olympus America Inc.,
Center Valley, PA). The grading scale for neuronal damage
in each region was scored as previously described [36]: 0,
normal (no apparent neuronal cell death); 1, fewer than
1/3 cells damaged; 2, more than 1/3 but less than 2/3
damaged; and 3, more than 2/3 of cells dead.
Quantification of hemorrhagic volume
Micro-hemorrhages were quantified in cresyl violet-
stained serial sections with stereology analysis technique
[39], which utilizes systematic sampling of 25 to 30 serial
sections per brain, each section separated by 200 μm
along the anteroposterior axis of each brain. Spontaneous
ICH after embolic ischemia was examined as described
[15], using a 4x objective lens. Additional validation was
carried out by capturing images using a 20x objective and
micro-hemorrhage area was measured using the ImageJ
analysis software. Care was taken to examine each serial
section to include multiple hemorrhage areas per section.
Hemorrhage area for each animal was summed and then
hemorrhage volumes were calculated by integrating the
appropriate area with the section interval thickness
(200 μm) and expressed as μm3.
Fluorescence labeling and immunohistochemistry
Cerebral vascular perfusion patterns were examined
after embolic cerebral ischemia using high-molecular
weight fluorescein-dextran. A modified PE-10 catheter
connected to a 1-cc syringe was inserted into the right
femoral vein and a solution of FITC-dextran [0.1 mL of
50 mg/mL in PBS; molecular weight (MW) 2,000 KDa,
Sigma Chemical Co, St. Louis, MO] was administered
for 30 minutes before the animal was sacrificed. Mice
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placed in 4% paraformaldehyde for 24 hours. Coronal
sections (100 μm thickness) were cut with a vibrotome
and post-fixed in 4% paraformaldehyde. For immunohis-
tochemistry, 40 μm thick brain sections were labeled for
microvessel endothelial cells using the specific glycopro-
tein Lycopersicon esculentum (tomato) lectin conjugated
to fluorescein (1:500, FL-1171; Vector Labs, Burlingame,
CA) or immunostained with the following antibodies: the
endothelial marker rat anti-CD31 (1:50, 550274; BD Bios-
ciences, San Diego, CA); the neuronal markers MAP-2
(1:200, M4403, Clone HM-2; Sigma Chemical Co, St. Louis,
MO) and NeuN (1:200, MAB377, Clone A60; Millipore-
Chemicon, Temecula, CA), and Fluoro-Jade B (0.0012%,
AG310; EMD-Millipore, Temecula, CA) fluorescence
staining for degenerating neurons; the ECM basement
membrane component laminin (1:200, L9393; Sigma
Chemical Co, St. Louis, MO); and the pericyte markers-
NG2 (1:200) described [46], desmin (1:50, M0760, Clone
D33; DakoCytomation, Carpinteria, CA), and α-SMA
(1:400, MS-113-P1ABX, Clone 1A4; Thermo Scientific-
Lab Vision, Fremont, CA); and mouse anti-ZO-1 anti-
body recognizing BBB tight-junction (1:50, 33–9100;
Invitrogen, San Diego, CA). Sections were then visua-
lized with fluorophore-conjugated secondary antibodies
(1:200, goat anti-mouse IgG-Alexa488, A11001; goat
anti-mouse IgG-Alexa594, A11005; and goat anti-rabbit
IgG-Alexa488, A110034; Invitrogen, San Diego, CA).
For double immunostaining, we incubated sections with
Pro-Block (PBK125; ScyTek, Logan, UT) for 5 minutes to
eliminate the need to match species with the fluorescence-
conjugated antibody, followed by incubation with normal
goat serum for 2 hours to block nonspecific binding before
applying the primary antibody. Specificity controls included
omitting the primary or secondary antibody. Sections were
counterstained with nuclear DNA dye Hoechst 33342 [29].
Fluorescence images were analyzed with a Leica DMI
6000B fully automated epifluorescence microscope includ-
ing AF6000 applications for deconvolution (Leica Micro-
systems Inc., Buffalo Grove, IL) or an Olympus XI-81
spin-disc scanning confocal microscope (Olympus Amer-
ica Inc., Center Valley, PA), and mosaic images were
stitched using Montage analysis tools (Slidebook™ from 3I,
Denver, CO) for image re-construction.
Measurement of pericytes
We quantified α-SMA-positive pericytes in 4–5 rando-
mized areas in the cortical penumbral region of the
lesioned hemisphere and the corresponding areas of the
contralateral side by counting approximately 1500 total
cells in each hemisphere. We calculated percentages of
α-SMA-positive pericytes and both α-SMA/laminin-
positive pericytes relative to total cells visualized by the
Hoechst dye staining [8,19,20] and measured theaverage lumen diameters of the long- and short-axis of
α-SMA labeled pericytes using the ImageJ software. The
long diameter (ΦL) is defined as the longest diameter in
the lumen circles, while the short diameter (ΦS) is
defined as the perpendicular bisector of the long diam-
eter. We compared percentages of laminin-positive peri-
cytes relative to total cells visualized by staining the
nuclear DNA of cells with Hoechst dye, and the overall
(laminin-positive and -negative) pericyte-encircled lumen
diameters.
Statistics
All experiments were performed in a randomized blinded
manner, with data analysis and experiments performed by
separate investigators. Each n number represents an indi-
vidual animal for each experiment. Data were analyzed
using Prism 5 software (GraphPad Software, La Jolla, CA)
by either paired or unpaired one-tailed Student's t-test
for two-group comparisons. All data are presented as
means ± SEM. Statistical significance was set at p< 0.05,
0.01 or 0.001, respectively.Additional files
Additional file 1: Figure S1. Testing specificity of the pericyte markers
α-SMA, NG2 and desmin by Immunohistochemistry. NG2 or desmin
monoclonal antibody (mAb) was used to detect pericytes with anti-
mouse IgG-Alexa488 (GαM Alexa-488; green), followed by
immunostaining with α-SMA mAb and visualized with anti-mouse
IgG-Alexa594 (GαM Alexa-594; red). Various immunohistochemistry
conditions for the double immunostainings with dual mAbs were
examined by omitting either the primary mAbs with the nuclear DNA
dye Hoechst for counter-staining the total cells. Immunohistochemistry
analysis reveals colocalization of α-SMA-positive cells with cells expressing
the pericyte markers NG2 (A) and desmin (B). Scale bars: 50 μm.
Additional file 2: Figure S2. Effect of SB-3CT on α-SMA-positive
pericytes after embolic ischemia. Pericytes were immunstained with
α-SMA mAb. Comparing images of α-SMA-positive pericytes in the
ischemic cortex with those in the corresponding contralateral region
reveals that treatment with SB-3CT partially protects pericytes from
ischemia-induced cell loss and lumen contraction after embolic MCA
occlusion in mice. Scale bars: 20 μm.
Additional file 3: Figure S3. Colocalization of dual endothelial markers.
Immunostaining of endothelial marker lectin (in green) with the endothelial
marker CD31 (in red) reveals colocalization of lectin-positive cells with the
endothelial marker CD31. DNA counterstaining with Hoechst 33324 reveals
total cells. Scale bars: 50 μm.
Additional file 4: Figure S4. Degradation of the tight-junction protein
ZO-1 after embolic ischemia. Merged images with DNA counterstain by
Hoechst 33324 reveals colocalization of laminin-positive microvessels (in
green) with the BBB tight-junction marker ZO-1 (in red). Representative
double immunostaining images in ischemic cortex penumbras are
compared with the corresponding contralateral regions. There are
degradation of the tight-junction protein ZO-1 and fragmentation of ECM
laminin-positive microvessels in the ischemic cortex. Scale bars: 50 μm.
Additional file 5: Figure S5. Protection against neurodegeneration by
prolonged treatment with SB-3CT for 7 days in mice after embolic ischemia.
Immunohischemistry using Fluoro-Jade B (in green) reveals
neurodegeneration in the ischemic cortex 7 days after embolus-induced
MCA occlusion in mice. SB-3CT treatment for 7 days significantly protects
against cortical neurodegeneration. Scale bars: 50 μm.
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